S. L. Kalinina
Research Subjects
S. L. Kalinina has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- S. V. Ignatyev
Kirov Research Institute of Hematology and Blood Transfusion
5 shared publications - Alexey V. Lyanguzov
Kirov Research Institute of Hematology and Blood Transfusion
4 shared publications - O. Yu. Sergunina
Kirov Research Institute of Hematology and Blood Transfusion
3 shared publications - I. A. Dokshina
Kirov Research Institute of Hematology and Blood Transfusion, Federal Medical and Biological Agency
2 shared publications - I. P. Tataurova
Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agency
2 shared publications - Igor Paramonov
Federal State‐Financed Scientific Institution: Kirov Research Institute of Hematology and Blood Transfusion Under the Federal Medical Biological Agency Kirov Russia
2 shared publications
Latest Publications
- 22 October 2025
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 5,p. 74-80
Endothelial factors for prediction of mortality in blood cancer patients with sepsis
Objective. To investigate predictive capability of serum von Willebrand factor (VWF:Ag) and syndecan-1 (SDC-1) in blood cancer patients with sepsis. Material and methods. The study encompassed a cohort of 71 blood cancer patients with sepsis between 2020 and 2022. Disease severity and organ dysfunction were evaluated using the Acute Physiology and Chronic Health Evaluation II (APACHE II), Simplified Acute Physiology Score II (SAPS II), and Sepsis-related Organ Failure Assessment (SOFA) scoring systems. Prognostic value of SDC-1 and VWF:Ag concentrations in predicting mortality was assessed. Results. The mortality rate was 39.4%. Comparative analysis of SDC-1 and VWF:Ag concentrations in patients with different outcomes revealed significantly higher concentrations of SDC-1 (Mann-Whitney U=217.0; p<0.001) and VWF:Ag (Mann-Whitney U=268.5; p<0.001) in dead patients. No significant differences were observed in procalcitonin and C-reactive protein (CRP) concentrations between survivors and non-survivors. Positive correlations were demonstrated between SDC-1 concentrations and SOFA scores (Spearman’s rho=0.338, p=0.004), as well as APACHE II scores (Spearman’s rho=0.346; p=0.003). Similarly, positive correlations were observed between VWF:Ag concentrations and APACHE II scores (Spearman’s rho=0.296; p=0.012), as well as APACHE II scores (Spearman’s rho=0.272, p=0.022). Survival analysis revealed significant differences in outcomes between patients with SDC-1 concentrations greater and less than the median (14 ng/ml) (log-rank χ2=5.77, p=0.016) and VWF:Ag concentrations greater and less than the median (383%) (log-rank χ2=11.74; p=0.0006). Multivariate analysis demonstrated a significant association between SDC-1 (OR=1.052; 95% CI 1.020—1.084; p=0.001) and VWF:Ag (OR=1.005; 95% CI 1.001—1.009; p=0.011) concentrations with mortality. Conclusion. SDC-1 and VWF:Ag concentrations may be potential biomarkers for predicting mortality in blood cancer patients with sepsis.
- 22 October 2025
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 5,p. 74-80
Endothelial factors for prediction of mortality in blood cancer patients with sepsis
Objective. To investigate predictive capability of serum von Willebrand factor (VWF:Ag) and syndecan-1 (SDC-1) in blood cancer patients with sepsis. Material and methods. The study encompassed a cohort of 71 blood cancer patients with sepsis between 2020 and 2022. Disease severity and organ dysfunction were evaluated using the Acute Physiology and Chronic Health Evaluation II (APACHE II), Simplified Acute Physiology Score II (SAPS II), and Sepsis-related Organ Failure Assessment (SOFA) scoring systems. Prognostic value of SDC-1 and VWF:Ag concentrations in predicting mortality was assessed. Results. The mortality rate was 39.4%. Comparative analysis of SDC-1 and VWF:Ag concentrations in patients with different outcomes revealed significantly higher concentrations of SDC-1 (Mann-Whitney U=217.0; p<0.001) and VWF:Ag (Mann-Whitney U=268.5; p<0.001) in dead patients. No significant differences were observed in procalcitonin and C-reactive protein (CRP) concentrations between survivors and non-survivors. Positive correlations were demonstrated between SDC-1 concentrations and SOFA scores (Spearman’s rho=0.338, p=0.004), as well as APACHE II scores (Spearman’s rho=0.346; p=0.003). Similarly, positive correlations were observed between VWF:Ag concentrations and APACHE II scores (Spearman’s rho=0.296; p=0.012), as well as APACHE II scores (Spearman’s rho=0.272, p=0.022). Survival analysis revealed significant differences in outcomes between patients with SDC-1 concentrations greater and less than the median (14 ng/ml) (log-rank χ2=5.77, p=0.016) and VWF:Ag concentrations greater and less than the median (383%) (log-rank χ2=11.74; p=0.0006). Multivariate analysis demonstrated a significant association between SDC-1 (OR=1.052; 95% CI 1.020—1.084; p=0.001) and VWF:Ag (OR=1.005; 95% CI 1.001—1.009; p=0.011) concentrations with mortality. Conclusion. SDC-1 and VWF:Ag concentrations may be potential biomarkers for predicting mortality in blood cancer patients with sepsis.
- Open Access
- 9 November 2022
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 9 (3) , 107-112-112
Atipical course of clostridial colitis in child with Hodgkin’s lymphoma
The wide antibiotics use in different areas of medicine has significantly increased the incidence of pseudomembranous colitis caused by Clostridium difficile. Strong necessity of antibacterial therapy in hematological patients is the reason of a higher frequency of this complication after programmed chemotherapy and hematopoietic stem cell transplantation. The atypical course of clostridial colitis makes it difficult to diagnose, leads to delay of treatment and fatal complications. We presented the case of clostridial colitis with atypical clinical manifestations in the 8-year-old child with Hodgkin’s lymphoma. Disease was complicated by colon perforation and fecal peritonitis, which required surgery and long-term rehabilitation. The analysis of publications devoted to clostridial colitis in patients with hematological malignancies was carried out and possible reasons of its atypical course was reviewed. The ways to improve the diagnosis, treatment and prevention of this serious complication are presented.
- 9 November 2022
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 9 (3) , 107-112-112
Open AccessAtipical course of clostridial colitis in child with Hodgkin’s lymphoma
The wide antibiotics use in different areas of medicine has significantly increased the incidence of pseudomembranous colitis caused by Clostridium difficile. Strong necessity of antibacterial therapy in hematological patients is the reason of a higher frequency of this complication after programmed chemotherapy and hematopoietic stem cell transplantation. The atypical course of clostridial colitis makes it difficult to diagnose, leads to delay of treatment and fatal complications. We presented the case of clostridial colitis with atypical clinical manifestations in the 8-year-old child with Hodgkin’s lymphoma. Disease was complicated by colon perforation and fecal peritonitis, which required surgery and long-term rehabilitation. The analysis of publications devoted to clostridial colitis in patients with hematological malignancies was carried out and possible reasons of its atypical course was reviewed. The ways to improve the diagnosis, treatment and prevention of this serious complication are presented.
- 9 December 2020
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 4,p. 102-108
Viscoelastic properties of a blood clot and the manifestations of hemorrhagic syndrome in thrombocytopeniс patients with hemoblastosis
Введение. Тромбоцитопения является частым осложнением онкогематологических заболеваний, которое провоцирует развитие геморрагического синдрома. Уровень тромбоцитов в периферической крови, являющийся пороговым для переливания концентрата тромбоцитов (КТ), окончательно не установлен. Применение тромбоэластографии (ТЭГ) при тромбоцитопениях у онкогематологических больных может повысить прогностические возможности определения риска кровотечений. Цель исследования: оценить вязко-эластические свой ства сгустка крови при тромбоцитопении менее 50×109/л и их взаимосвязь с проявлениями геморрагического синдрома у онкогематологических больных. Материалы и методы. В исследование включено 84 пациента с гемобластозами и тромбоцитопенией менее 50×109/л, 54 (64%) мужчины и 30 (36%) женщин, медиана возраста — 54 года. В зависимости от уровня тромбоцитов в периферической крови пациентов разделили на 2 группы: группа 1 — 44 пациента с числом тромбоцитов от 25 до 50×109/л, группа 2 — 40 больных с содержанием тромбоцитов менее 25×109/л. Исследовали показатели периферической крови, коагулограммы и ТЭГ. Степень тяжести кровотечений оценивали по шкале проявлений геморрагического синдрома (ВОЗ) и по шкале оценки побочных явлений Национального института рака (США). Результаты. Гипокоагуляция по ТЭГ в группе 1 выявлена в 46% случаев, в группе 2 — в 75%. Значимые межгрупповые различия показателей ТЭГ получены только в отношении максимальной амплитуды. Геморрагический синдром в группе 1 диагностирован у 6 (13%) пациентов, в группе 2 — у 14 (35%). Однако предиктивная роль влияния количества тромбоцитов на частоту развития геморрагического синдрома не установлена (β = 0,016; p = 0,92). Сочетание тромбоцитопении и гипокоагуляции по ТЭГ проявлялось в виде геморрагического синдрома в 3,3 раза чаще, чем без гипокоагуляции (RR = 3,3; 95% ДИ = 1,20–9,05). В ряде случаев основанная на результатах ТЭГ трансфузионная тактика позволила избежать переливания КТ при инвазивных манипуляциях у больных с тромбоцитопенией менее 25 × 109 / л. Заключение. Глубина тромбоцитопении не является надежным предиктором геморрагического синдрома. Применение ТЭГ у пациентов с тромбоцитопенией позволяет оптимизировать трансфузионную тактику, избежав ненужных переливаний КТ. Сочетание тяжелой тромбоцитопении с гипокоагуляцией по данным ТЭГ служит показанием для профилактических трансфузий КТ. Background. Thrombocytopenia is a frequent complication of hemoblastosis that causes hemorrhagic syndrome. The threshold of peripheral blood platelet count for transfusion of platelet concentrate is discussed. Thromboelastography (TEG) can be considered as additional prognostic method for bleeding risk assessment in thrombocytopenic patients with leukemia. Objectives: to study changes in the viscoelastic properties of blood clot in hemoblastosis patients with thrombocytopenia less than 50×109/L and their relationship with the manifestations of hemorrhagic syndrome. Patients/ Methods. The study included 84 hemoblastosis patients — 54 (64%) men и 30 (36%) women with thrombocytopenia less than 50 × 109/L, median age — 54 years. All patients are divided into 2 groups according to the platelet count: Group 1 — 25–50×109/L, Group 2 — less than 25×109/L. Peri pheral blood counts, TEG and coagulogram parameters were evaluated in both groups. Manifestations of hemorrhagic syndrome were assessed according to the WHO bleeding scale and Common terminology criteria for adverse events of the National Cancer Institute (USA). Results. Hypocoagulation according TEG in Group 1 was found in 46% of cases, in Group 2 — in 75%. Significant intergroup differences in TEG parameters were obtained only in maximum amplitude. Hemorrhagic syndrome in Group 1 diagnosed in 6 (14%) patients, in Group 2 — in 14 (35%). There was no dependence of hemorrhagic syndrome frequency on the severity of thrombocytopenia (β = 0.016; p = 0.92). The combination of thrombocytopenia and hypocoagulation according TEG manifested as a hemorrhagic syndrome 3.3 times more often than without hypocoagulation (RR...
- 9 December 2020
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 4,p. 102-108
Viscoelastic properties of a blood clot and the manifestations of hemorrhagic syndrome in thrombocytopeniс patients with hemoblastosis
Введение. Тромбоцитопения является частым осложнением онкогематологических заболеваний, которое провоцирует развитие геморрагического синдрома. Уровень тромбоцитов в периферической крови, являющийся пороговым для переливания концентрата тромбоцитов (КТ), окончательно не установлен. Применение тромбоэластографии (ТЭГ) при тромбоцитопениях у онкогематологических больных может повысить прогностические возможности определения риска кровотечений. Цель исследования: оценить вязко-эластические свой ства сгустка крови при тромбоцитопении менее 50×109/л и их взаимосвязь с проявлениями геморрагического синдрома у онкогематологических больных. Материалы и методы. В исследование включено 84 пациента с гемобластозами и тромбоцитопенией менее 50×109/л, 54 (64%) мужчины и 30 (36%) женщин, медиана возраста — 54 года. В зависимости от уровня тромбоцитов в периферической крови пациентов разделили на 2 группы: группа 1 — 44 пациента с числом тромбоцитов от 25 до 50×109/л, группа 2 — 40 больных с содержанием тромбоцитов менее 25×109/л. Исследовали показатели периферической крови, коагулограммы и ТЭГ. Степень тяжести кровотечений оценивали по шкале проявлений геморрагического синдрома (ВОЗ) и по шкале оценки побочных явлений Национального института рака (США). Результаты. Гипокоагуляция по ТЭГ в группе 1 выявлена в 46% случаев, в группе 2 — в 75%. Значимые межгрупповые различия показателей ТЭГ получены только в отношении максимальной амплитуды. Геморрагический синдром в группе 1 диагностирован у 6 (13%) пациентов, в группе 2 — у 14 (35%). Однако предиктивная роль влияния количества тромбоцитов на частоту развития геморрагического синдрома не установлена (β = 0,016; p = 0,92). Сочетание тромбоцитопении и гипокоагуляции по ТЭГ проявлялось в виде геморрагического синдрома в 3,3 раза чаще, чем без гипокоагуляции (RR = 3,3; 95% ДИ = 1,20–9,05). В ряде случаев основанная на результатах ТЭГ трансфузионная тактика позволила избежать переливания КТ при инвазивных манипуляциях у больных с тромбоцитопенией менее 25 × 109 / л. Заключение. Глубина тромбоцитопении не является надежным предиктором геморрагического синдрома. Применение ТЭГ у пациентов с тромбоцитопенией позволяет оптимизировать трансфузионную тактику, избежав ненужных переливаний КТ. Сочетание тяжелой тромбоцитопении с гипокоагуляцией по данным ТЭГ служит показанием для профилактических трансфузий КТ. Background. Thrombocytopenia is a frequent complication of hemoblastosis that causes hemorrhagic syndrome. The threshold of peripheral blood platelet count for transfusion of platelet concentrate is discussed. Thromboelastography (TEG) can be considered as additional prognostic method for bleeding risk assessment in thrombocytopenic patients with leukemia. Objectives: to study changes in the viscoelastic properties of blood clot in hemoblastosis patients with thrombocytopenia less than 50×109/L and their relationship with the manifestations of hemorrhagic syndrome. Patients/ Methods. The study included 84 hemoblastosis patients — 54 (64%) men и 30 (36%) women with thrombocytopenia less than 50 × 109/L, median age — 54 years. All patients are divided into 2 groups according to the platelet count: Group 1 — 25–50×109/L, Group 2 — less than 25×109/L. Peri pheral blood counts, TEG and coagulogram parameters were evaluated in both groups. Manifestations of hemorrhagic syndrome were assessed according to the WHO bleeding scale and Common terminology criteria for adverse events of the National Cancer Institute (USA). Results. Hypocoagulation according TEG in Group 1 was found in 46% of cases, in Group 2 — in 75%. Significant intergroup differences in TEG parameters were obtained only in maximum amplitude. Hemorrhagic syndrome in Group 1 diagnosed in 6 (14%) patients, in Group 2 — in 14 (35%). There was no dependence of hemorrhagic syndrome frequency on the severity of thrombocytopenia (β = 0.016; p = 0.92). The combination of thrombocytopenia and hypocoagulation according TEG manifested as a hemorrhagic syndrome 3.3 times more often than without hypocoagulation (RR...
- Open Access
- 4 July 2020
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 7 (2) , 35-41
Use of totally implantable venous port systems in children hematology clinic
Relevance.Reliable and long-term venous access is one of the most important condition for a successful leukemia therapy in children. Safe and convenient access to a central vein allows to provide chemotherapy, adjuvant treatment, parenteral nutrition and blood transfusion. It decreases the likelihood of phlebitis development and reduction of the peripheral venous network in comparison with peripheral venous access. The use of totally implantable venous port systems reduces risks of severe complications associated with re-catheterization of the central vein thus it improves patient’s quality of life.The purpose of the studyis a retrospective assessment of the experience of use and analysis of the complications of totally implantable venous port systems in children with diseases of the blood system.Materials and methods.The data of 61 patients of the pediatric hematology clinic with venous port systems have been analyzed.Results.Perioperative complications developed in 3 (4.9 %) patients Median time of using of port systems was 679 catheter-days. Delayed complications requiring removal of the device developed in 8 (13.1 %) patients. Infectious complications were the reason for device removal in 3 (2.9 %) patients, mechanical complications in 5 (8.2 %) patients. No thrombotic complications were found.Conclusions.The use of venous port systems in children with hematologic diseases for a long period of time is an effective and safe way for central venous access providing.
- 4 July 2020
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 7 (2) , 35-41
Open AccessUse of totally implantable venous port systems in children hematology clinic
Relevance.Reliable and long-term venous access is one of the most important condition for a successful leukemia therapy in children. Safe and convenient access to a central vein allows to provide chemotherapy, adjuvant treatment, parenteral nutrition and blood transfusion. It decreases the likelihood of phlebitis development and reduction of the peripheral venous network in comparison with peripheral venous access. The use of totally implantable venous port systems reduces risks of severe complications associated with re-catheterization of the central vein thus it improves patient’s quality of life.The purpose of the studyis a retrospective assessment of the experience of use and analysis of the complications of totally implantable venous port systems in children with diseases of the blood system.Materials and methods.The data of 61 patients of the pediatric hematology clinic with venous port systems have been analyzed.Results.Perioperative complications developed in 3 (4.9 %) patients Median time of using of port systems was 679 catheter-days. Delayed complications requiring removal of the device developed in 8 (13.1 %) patients. Infectious complications were the reason for device removal in 3 (2.9 %) patients, mechanical complications in 5 (8.2 %) patients. No thrombotic complications were found.Conclusions.The use of venous port systems in children with hematologic diseases for a long period of time is an effective and safe way for central venous access providing.
- Open Access
- 25 July 2019
- Published by Publishing House ABV Press in Oncohematology
- Vol. 14 (2)
Extramedular lesions of a small intestinum in acute myeloid leukemia: case report and literature review
Currently, the diagnosis of acute myeloid lekemia is based on the standards of morphological studies and immunophenotyping of the bone marrow. The manifestation of the disease can be accompanied by extramedullary lesions, which are difficult to verify. The article presents a case of diagnosis of acute myeloid lekemia in an elderly w oman, occurring with a leukemic lesion of the small in - testine. Morphological studies and immunophenotyping of small intestine biopsy revealed acute myeloid lekemia blast tumor cells. Difficulties of examination in such cases lead to late revealing of leukemic infiltrates of rare localization and significantly worsen the prognosis.
- 25 July 2019
- Published by Publishing House ABV Press in Oncohematology
- Vol. 14 (2)
Open AccessExtramedular lesions of a small intestinum in acute myeloid leukemia: case report and literature review
Currently, the diagnosis of acute myeloid lekemia is based on the standards of morphological studies and immunophenotyping of the bone marrow. The manifestation of the disease can be accompanied by extramedullary lesions, which are difficult to verify. The article presents a case of diagnosis of acute myeloid lekemia in an elderly w oman, occurring with a leukemic lesion of the small in - testine. Morphological studies and immunophenotyping of small intestine biopsy revealed acute myeloid lekemia blast tumor cells. Difficulties of examination in such cases lead to late revealing of leukemic infiltrates of rare localization and significantly worsen the prognosis.